A marketing authorization, a CE mark, a listing — these let you sell in Germany. They do not tell you whether you'll be paid, at what price, or whether anyone will use the product. That gap is where most market entries stall, and closing it is the whole job.
Getting authorized and getting paid are two different projects. Authorization is the entry ticket; revenue is decided afterwards — by the reimbursement decision, the negotiated price, the code, the distribution channel and the relationships payers, hospitals and partners expect. The “how to enter Germany” layer is commodity and increasingly free. The defensible work — and where entries succeed or quietly fail — is closing the gap between authorized and paid.
Most companies plan for approval. Far fewer plan for what happens after it — and in Germany, that's where the money is decided.
A drug can be authorized, a device CE-marked, an app listed on the DiGA directory — and still generate no revenue. Because the German system doesn't pay you for being allowed to sell; it pays you once a separate set of decisions goes your way. Miss that, and you discover the ceiling after you've built the cost base.
Getting in is the easy part. Getting paid is the work.
Authorization and revenue sit at two ends. Everything that decides whether you get from one to the other lives in the middle — and none of it is granted by the approval.
The approval hands you the left box. Nothing in the middle comes with it — and the middle is where the revenue is won or lost.
Germany's system is built to control what it pays. Authorization protects patients from unsafe products; a separate machinery protects the statutory system from overpaying. The two are deliberately decoupled.
So the market rewards structure before visibility: choose the right reimbursement route, the right commercial model and the right local presence first, and the market reads everything else from there. Companies that treat reimbursement and access as a post-launch formality find the ceiling after the budget is already committed.
The gap is real in every life-sciences track — but each one runs on a different mechanism. Pretending one playbook covers all three is exactly what a generalist would do.
A marketing authorization lets you launch; AMNOG and the G-BA benefit assessment set the price ceiling.
AMNOG explained → MedtechA CE mark lets you sell; hospital DRG / NUB vs outpatient G-BA / EBM decide payment by setting.
Device reimbursement → Digital HealthA DiGA listing makes you reimbursable; getting physicians to prescribe is a separate battle.
DiGA route →The reason this matters commercially: the easy layer is free, and the hard layer is defensible.
“How to enter Germany” — entity, tax, first steps — is well covered by public agencies, and now answered by any AI tool. It's useful, but it's a commodity. The defensible layer is the one nobody hands you: regulated market access, on-the-ground execution, and named humans accountable for the outcome. That's the layer worth paying for — and the layer we own.
The free layer gets you authorized. The defensible layer gets you paid.
The same thesis runs in reverse. A German company going abroad meets another country's version of the gap — a Saudi SFDA registration that doesn't guarantee an NUPCO tender, an Indian import licence that still needs distribution and adoption. Reading a regulated market and closing its gap is one discipline, whichever direction you cross the border.
Registered isn't procured. Authorized isn't paid. Same idea, mirrored.
Closing the gap is a mix of things one boutique can't credibly do all in-house — so we own the layer that decides revenue and orchestrate the rest.
Tell us your product and direction — we'll map the realistic route from approval to revenue, and own the hard part in between.
Book a Market Access Session →